Peter H. Kalinka
Longmore 60 Biotech Inc., USA
Title: Development of biologics and biosimilars in emerging markets: Challenges
Biography
Biography: Peter H. Kalinka
Abstract
Peter H Kalinka is Chairman and Principal Consultant at Longmore 60 Biotech Inc. He possesses in-depth knowledge of drug development and directed numerous development projects including Therapeutic Proteins, Monoclonal Antibodies, and Fusion Proteins. His experience in overall development spans cloning, process development, scale-up, (e-coli, CHO, Hybridoma etc.) analytical development, bioassays, pre-clinical, clinical Phases, to manufacturing and regulatory affairs. Working with more than 20 companies worldwide, he has directed all or spearheaded parts of development programs for Biosimilars, Biobetters, and Biologics.